FMT for Hepatic Encephalopathy? The THEMATIC Trial aims to make is a ‘no brainer’

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-03-25 DOI:10.1016/j.jhep.2025.03.009

Debbie L. Shawcross, Vishal C. Patel

引用次数: 0

Abstract

Section snippets

Conflict of interest

DLS has undertaken consultancy for Norgine Pharmaceuticals Ltd, EnteroBiotix, MRM Health, Satellite Biosciences, Apollo Therapeutics Ltd and Genfit and has delivered paid lectures for Norgine Pharmaceuticals Ltd.VCP has undertaken consultancy for Norgine Pharmaceuticals Ltd, Alfasigma S.p.A. Menarini Diagnostics Ltd. and AstraZeneca UK and has delivered paid lectures for Norgine Pharmaceuticals Ltd.Please refer to the accompanying ICMJE disclosure forms for further details.

Authors’ contributions

Both authors contributed equally to the writing of this editorial.

Financial support

No funding was received for the preparation of this manuscript.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.